natgillin/translations-raw huggingface dataset:
Response rates and p-values for PASI and PGA were estimated based on a logistic regression model where missing data were imputed using multiple imputation based on the MCMC method.
Stopnje odziva in vrednosti p za PASI in PGA so bile ocenjene na podlagi modela logistične regresije, kjer so bili manjkajoči podatki vstavljeni z multiplo imputacijo na podlagi metode MCMC.
In addition, Studies RA-I and RA-II had a mandatory withdrawal for non-responders at Week 16, the majority of whom were on placebo.
Poleg tega je bila v okviru študij RA-I in RA-II za bolnike, ki se na zdravljenje niso odzivali in katerih večina je prejemala placebo, obvezna prekinitev zdravljenja po 16 tednih.
The primary endpoint of the study was the ACR 20 responder rate at week 34.
Primarni cilj študije je bil odziv ACR 20 v 34. tednu.
In women, ASAS20 responses were not statistically significantly different from placebo until after the Week 12 time point.
Pri ženskah so bili odzivi ASAS20 v primerjavi s placebom statistično značilno različni po 12. tednu.
In CIMPASI-1 and CIMPASI-2, sixty patients were antibody positive, 27 of these patients were evaluable for neutralizing antibodies and tested positive.
V študiji CIMPASI-1 in CIMPASI-2 je bilo šestdeset bolnikov pozitivnih na protitelesa, med njimi je bilo pri 27 možno oceniti nevtralizirajoča protitelesa in so imeli pozitiven rezultat testa.
In patients who develop HBV reactivation, Cimzia should be stopped and effective anti-viral therapy with appropriate supportive treatment should be initiated.
Pri bolnikih, pri katerih se razvije reaktivacija HBV, je treba zdravljenje z zdravilom Cimzia prekiniti, ter začeti z učinkovito protivirusno terapijo in ustreznim podpornim zdravljenjem.
• This is followed by a maintenance dose of 200 mg every 2 weeks.
• Temu sledi vzdrževalni odmerek 200 mg vsak 2. teden.
In the CIMPACT study, the primary efficacy endpoint was the proportion of patients achieving PASI 75 at Week 12.
V študiji CIMPACT je bil primarni opazovani dogodek učinkovitosti delež bolnikov, ki so v 12. tednu dosegli PASI 75.
In addition, since certolizumab pegol is a protein that is degraded in the gastrointestinal tract after oral administration, the absolute bioavailability is expected to be very low in a breastfed infant.
Poleg tega je certolizumab pegol beljakovina, ki se po peroralnem zaužitju razgradi v prebavilih, zato je absolutna biološka uporabnost pri dojenem otroku pričakovano zelo majhna.
The primary efficacy endpoint was the ASAS20 response rate at Week 12.
Primarni cilj študije učinkovitosti je bil odziv ASAS20 v 12. tednu.
Improvements in all afore mentioned outcomes were maintained through Week 48.
Izboljšanja vseh zgoraj omenjenih izidov so se ohranila vseskozi do 48. tedna.
• the treatment of moderate to severe, active rheumatoid arthritis (RA) in adult patients when the response to disease-modifying antirheumatic drugs (DMARDs) including MTX, has been inadequate.
• zdravljenju zmernega do hudega aktivnega revmatoidnega artritisa (RA) pri odraslih bolnikih, pri katerih je bil odziv na imunomodulirajoča antirevmatična zdravila (DMARD), vključno z MTX, neustrezen.
Use of TNF-antagonists has been associated with rare cases of new onset or exacerbation of clinical symptoms and/or radiographic evidence of demyelinating disease, including multiple sclerosis.
Uporaba zdravil, ki zavirajo TNF, je bila v redkih primerih povezana s pojavom ali poslabšanjem kliničnih simptomov in/ali radiografskih dokazov demielizinirajoče bolezni, vključno z multiplo sklerozo.
• worsening of a condition called dermatomyositis (seen as a skin rash accompanying muscle weakness)
• poslabšanje stanja, imenovanega dermatomiozitis (viden kot kožni izpuščaj, ki ga spremlja mišična šibkost)
• You can now remove the used pen by pulling the pen straight up carefully from the skin.
• Uporabljeni peresnik lahko odstranite tako, da ga previdno potegnete iz kože naravnost navzgor.
In both studies, the safety profile for these patients was consistent with the safety profile in rheumatoid arthritis and previous experience with Cimzia.
Varnostni profil pri teh bolnikih je bil v obeh študijah skladen z varnostnim profilom pri revmatoidnem artritisu in s prejšnjimi izkušnjami z zdravilom Cimzia.
Table 1 Adverse reactions in clinical trials and postmarketing System Organ Class
Preglednica 1 Neželeni učinki v kliničnih študijah in v obdobju trženja Organski sistem
• Remove the following items from the Cimzia pack and set them up on a clean flat surface:
• Iz škatlice z zdravilom Cimzia vzemite naslednje pripomočke in jih razporedite po čisti, ravni površini:
What you need to know before you use Cimzia
Kaj morate vedeti, preden boste uporabili zdravilo Cimzia
Among patients remaining in the study, ACR 20, 50 and 70 response rates were maintained through Week 216.
Med bolniki, ki so ostali v študiji, so odzivi ACR 20, ACR 50 in ACR 70 trajali do 216. tedna.
- Do not heat the medication - let it warm up on its own.
- Zdravila ne segrevajte - naj se segreje samo.
Patients who miss a dose should be advised to inject the next dose of Cimzia as soon as they remember and then continue injecting subsequent doses as instructed.
Bolnikom, ki so izpustili odmerek, svetujemo, da si naslednji odmerek zdravila Cimzia vbrizgajo takoj, ko je to mogoče, ter nato z aplikacijo nadaljnjih odmerkov nadaljujejo po navodilih.
• changed numbers of blood cells, including low red cell count (anaemia), low platelet counts,
• spremembe števila krvnih celic, vključno z majhnim številom rdečih krvnih celic (anemija),
• With the other hand, hold the syringe at a 45-degree angle to the skin.
• Z drugo roko primaknite brizgo h koži pod kotom 45 stopinj.
In all situations described below, the benefit/risk balance of Cimzia therapy should be very carefully considered.
V vseh situacijah, opisanih v nadaljevanju, je treba zelo skrbno pretehtati prednosti in tveganja zdravljenja z zdravilom Cimzia.
The CPK elevations in the axSpA study were mostly mild to moderate, transient in nature and of unknown clinical significance with no cases leading to withdrawal.
V axSpA študiji so bila zvišanja CPK vrednosti večinoma blaga do zmerna, prehodne narave in neznanega kliničnega pomena, brez primerov prekinitve zdravljenja.
The solution is clear to opalescent, colourless to yellow.
Raztopina je bistra do opalescentna, brezbarvna do rumena.
• skin cancers, pre-cancerous skin lesions
• kožni rak, predrakave kožne lezije
Previous treatment with one TNF-antagonist was allowed and 20% of patients had prior TNF-antagonist exposure.
Predhodno zdravljenje z zaviralci TNF je bilo dovoljeno in 20 % bolnikov je bilo predhodno zdravljenih z zaviralci TNF.
p value was estimated from an ANCOVA model on the ranks with treatment, region, time since RA diagnosis at Baseline (≤4 months vs >4 months) as factors and Baseline rank as a covariate.
p vrednost je bila ocenjena iz modela ANCOVA s faktorji za zdravljenje, področje in čas od diagnoze RA v izhodiščni vrednosti (≤ 4 mesecev v primerjavi z > 4 mesecev) in izhodiščno vrednostjo kot kovariata.
Latex-sensitivity
Občutljivost na lateks
- If you are at risk of or are a carrier of or have active HEPATITIS B VIRUS (HBV) infection, Cimzia may increase the risk of reactivation in people who carry this virus.
- Če pri vas obstaja tveganje za okužbo z VIRUSOM HEPATITISA B (HBV), če ste njegov prenašalec ali pa imate aktivno okužbo, lahko pri osebah, ki so prenašalci virusa, zdravilo Cimzia poveča tveganje reaktivacije.
However, population pharmacokinetic analysis based on subjects with mild renal impairment showed no effect of creatinine clearance.
Vendar pa populacijska farmaokinetična analiza oseb z blagimi motnjami v delovanju ledvic ni pokazala nobenega učinka na očistek kreatinina.
Eighteen percent of patients reported a history of psoriatic arthritis at baseline.
Osemnajst odstotkov bolnikov je ob izhodišču poročalo o psoriatičnem artritisu v anamnezi.
Since tumour necrosis factor (TNF) mediates inflammation and modulates cellular immune responses, the possibility exists for TNF-antagonists, including Cimzia, to cause immunosupression, affecting host defences against infections and malignancies.
Ker tumorje nekrotizirajoči faktor (TNF) deluje kot prenašalec vnetja in modulira imunske odzive celic, obstaja možnost, da zaviralci TNF, vključno z zdravilom Cimzia, povzročijo imunosupresijo ter prizadenejo obrambo organizma proti okužbam in malignim obolenjem.
Certolizumab pegol plasma concentrations measured in 14 infants at birth were Below the Limit of Quantification (BLQ) in 13 samples; one was 0.042 µg/ml with an infant/mother plasma ratio at birth of 0.09%.
Koncentracije certolizumab pegola v plazmi, izmerjene pri 14 dojenčkih ob rojstvu, so bile pri 13 vzorcih pod mejo kvantifikacije (BLQ-Below the Limit of Quantification); pri enem vzorcu je bila koncentracija 0,042 µg/ml, razmerje koncentracij v plazmi pri materi in dojenčkom ob rojstvu pa je bilo 0,09 %.
Other disorders - Patients with chronic obstructive pulmonary disease (COPD), or who are heavy smokers, may be at increased risk for cancer with Cimzia treatment.
- Bolniki s kronično obstruktivno pljučno boleznijo (KOPB) ali bolniki, ki so hudi kadilci, so med zdravljenjem z zdravilom Cimzia lahko izpostavljeni povečanemu tveganju za nastanek raka.
- After a short pause, ava will automatically pull the cartridge in further.
- Po krajši pavzi naprava ava avtomatsko povleče vložek.
Additionally, the observed incidence of antibodies in an assay may be influenced by several factors including sample handling, timing of sample collection, concomitant medicinal products, and underlying disease.
Poleg tega lahko na opazovano pogostnost protiteles v testu vpliva več dejavnikov, med drugim ravnanje z vzorcem, čas jemanja, sočasno jemanje drugih zdravil in osnovna bolezen.
Cimzia in combination with methotrexate can also be used to treat severe, active and progressive rheumatoid arthritis without previous use of methotrexate or other medicines.
Zdravilo Cimzia v kombinaciji z metotreksatom se lahko uporablja tudi za zdravljenje hudega, aktivnega in progresivnega revmatoidnega artritisa brez predhodne uporabe metotreksata ali drugih zdravil.
The symptoms described above can be due to some of the side effects listed below, which have been observed with Cimzia:
Zgoraj opisani simptomi so lahko posledica nekaterih v nadaljevanju navedenih neželenih učinkov, ki so jih opazili pri zdravljenju z zdravilom Cimzia:
A risk for development of hepatosplenic T-cell lymphoma in patients treated with Cimzia cannot be excluded.
Tveganja za razvoj hepatospleničnega limfoma celic T pri bolnikih, zdravljenih z zdravilom Cimzia, ni mogoče izključiti.
Pharmacotherapeutic group: immunosuppressants, tumour necrosis factor alpha (TNFα) inhibitors, ATC code: L04AB05
Farmakoterapevtska skupina: zdravila za zaviranje imunske odzivnosti, zaviralci tumorjenekrotizirajočega faktorja alfa (TNF-α), oznaka ATC: L04AB05
Treatment with Cimzia may result in the formation of antinuclear antibodies (ANA) and, uncommonly, in the development of a lupus-like syndrome (see section 4.8).
Zdravljenje z zdravilom Cimzia lahko pripelje do tvorbe avtoprotiteles (ANA) in v redkih primerih do razvoja lupusu podobnega sindroma (glejte poglavje 4.8).
• Continue to hold the pre-filled pen in place firmly against the skin until a second “click” is heard and the viewing window turns orange.
• Napolnjeni injekcijski peresnik še naprej čvrsto držite potisnjenega v kožo, dokler ne slišite drugi ˝klik˝ in se okence obarva oranžno.
Patients were evaluated in a double-blind placebo-controlled manner through Week 48.
Bolniki so bili ocenjeni na dvojno slepi, s placebom nadzorovan način, do konca 48. tedna.
Among patients remaining in the study, who had both baseline values and week 204 values, inhibition of inflammatory signs in both the sacroiliac joints (n=72) and spine (n=82) was largely maintained through Week 204 in the overall axial spondyloarthritis population as well as in both the AS and the nr-axSpA subpopulations.
Med bolniki, ki so ostali v študiji, in so imeli tako osnovne vrednosti kot tudi vrednosti v 204. tednu, je inhibicija vnetnih znakov v sakroilikalnih sklepih (n=72) in hrbtenici (n=82) trajala do 204. tedna pri celotni populaciji z aksialnim spondiloartritisom kot tudi pri podpopulacijah z AS in nr-axSpA.
Allée de la Recherche 60 B-1070 Bruxelles Belgium
Allée de la Recherche 60 B-1070 Bruselj Belgija
Cimzia should be used with caution in patients with mild heart failure (NYHA class I/II).
Zdravilo Cimzia moramo pri bolnikih z blagim srčnim popuščanjem (razred NYHA I/II) uporabljati previdno.
These diseases are inflammatory diseases of the spine.
Ti bolezni sta vnetni bolezni hrbtenice.
Tell your doctor IMMEDIATELY if you notice any of the following side effects:
NEMUDOMA obvestite svojega zdravnika, če ste opazili katerega od naslednjih neželenih učinkov:
A pharmacodynamic model based on the Phase III trial data predicts that around 15% of the patients develop antibodies in 6 months at the recommended dose regimen (200 mg every 2 weeks following a loading dose) without MTX co-treatment.
Farmakodinamski model, oblikovan na osnovi rezultatov študije faze III, predvideva, da se pri približno 15 % bolnikov v 6 mesecih ob priporočenem režimu odmerjanja (200 mg enkrat na dva tedna po udarnem odmerku) brez sočasnega zdravljenja z MTX razvijejo protitelesa.
At both Week 12 and 52, ASAS 40 responses were significantly greater than placebo.
V 12. in 52. tednu so bili odzivi ASAS 40 bistveno večji kot pri placebu.
- Position ava at a right angle on your skin with the screen facing you.
- Namestite napravo ava na kožo pod desnim kotom, tako da je zaslon obrnjen proti vam.
- Avoid removing ava from the skin during the injection to ensure that you receive the full dose.
- Med injiciranjem se izogibajte umikanju naprave ava s kože, da boste zagotovo prejeli polni odmerek
Inject within 5 minutes of removing the needle cap.
Injicirajte v 5 minutah po odstranitvi pokrovčka z igle.
• sexual dysfunction
• motnje spolne funkcije
Of the 850 patients randomized to receive placebo or Cimzia in these placebo-controlled studies, 29% of patients were naïve to prior systemic therapy for the treatment of psoriasis.
Med 850 bolniki, ki so bili v teh s placebom nadzorovanih študijah randomizirani za prejemanje placeba ali zdravila Cimzia, 29 % bolnikov predhodno še ni bilo zdravljenih s sistemsko terapijo za zdravljenje psoriaze.
Similar to the placebo-controlled studies, antibody positivity was associated with reduced efficacy in some patients.
Podobno kot pri s placebom nadzorovanih študijah so bili pozitivni rezultati na protitelesa povezani z zmanjšano učinkovitostjo pri nekaterih bolnikih.
The clearance following subcutaneous dosing in patients with psoriasis was 14 ml/h with an inter-subject variability of 22.2% (CV).
Očistek po subkutanem dajanju bolnikom s psoriazo je bil 14 ml/h z 22,2 % razlikami med osebami (CV).
Inhibition of radiographic progression was maintained with Cimzia treatment up to Week 48 in the subset of patients at higher risk of radiographic progression (patients with a Baseline mTSS score of > 6).
Radiografsko potrjeno zaviranje napredovanja bolezni se je z zdravljenjem z zdravilom Cimzia ohranilo do 48. tedna v podskupini bolnikov z večjim tveganjem za radiografsko potrjeno napredovanje bolezni (bolniki z izhodiščno vrednostjo pri oceni mTSS > 6).
• When “Remove and discard used medication” is shown, pull out the medication using the needle cap.
• Ko se prikaže ˝Remove and discard used medication˝, izvlecite vložek s pomočjo pokrovčka igle.
If inactive (‘latent') tuberculosis is suspected, a physician with expertise in the treatment of tuberculosis should be consulted.
V primeru suma na neaktivno (latentno) tuberkulozo se je potrebno posvetovati z zdravnikom, ki je strokovnjak za tuberkulozo.
Patients must have been intolerant to or had an inadequate response to at least two NSAIDs.
Bolniki prav tako niso prenašali ali so imeli neustrezen odziv na vsaj dve zdravili NSAID.
The clinical significance of low levels certolizumab pegol for infants is unknown.
Klinični pomen majhnih koncentracij certolizumab pegola pri dojenčkih ni znan.
To complete your injection: o Repeat Step 2 (Choosing and preparing an injection site), using a different injection site o Press ava firmly against the skin to begin the injection again, then o Press the (Start/Pause button).
o Ponovite korak 2 (Izbira in priprava mesta za injiciranje), vendar uporabite drugo mesto injiciranja o Pritisnite napravo ava tesno h koži, da se ponovno začne injiciranje.
Co-administration of Cimzia with methotrexate had no significant effect on the pharmacokinetics of methotrexate.
Sočasna uporaba zdravila Cimzia in metotreksata ni imela pomembnega učinka na farmakokinetiko metotreksata.
Do not try to touch the needle as it could activate the pre-filled pen.
Ne poskušajte se je dotakniti, ker bi lahko s tem aktivirali napolnjeni injekcijski peresnik.
One Cimzia pack contains:
Eno pakiranje zdravila Cimzia vsebuje:
If you forget to use Cimzia
Če ste pozabili uporabiti zdravilo Cimzia
One case of lymphoma was also observed in the Phase III psoriatic arthritis clinical trial.
En primer limfoma so opazili v fazi III kliničnega preskušanja zdravljenja psoriatičnega artritisa.
There is no evidence that Cimzia therapy has an effect on coagulation in vivo.
Nobenih dokazov ni, da zdravljenje z zdravilom Cimzia vpliva na koagulacijo in vivo.
In the placebo-controlled trial in patients with non-radiographic axial spondyloarthritis, using a more sensitive and drug tolerant assay than in previous trials, the overall incidence of patients who were antibody positive to certolizumab pegol was 97% (248/255 patients) after up to 52 weeks of treatment.
V s placebom nadzorovanem preskušanju pri bolnikih z neradiografskim aksialnim spondiloartritisom z uporabo bolj občutljivega in na zdravilo odpornejšega testa v primerjavi s prejšnjimi preskušanji je bila skupna incidenca bolnikov, ki so bili pozitivni na protitelesa proti certolizumab pegolu, 97 % (248/255 bolnikov) do 52. tedna zdravljenja.
Serious infections also included invasive opportunistic infections (e.g. pneumocystosis, fungal oesophagitis, nocardiosis and herpes zoster disseminated).
Med resnimi okužbami so bile invazivne oportunistične okužbe (npr. pnevmocistoza, glivični ezofagitis, nokardioza in diseminirani herpes zoster).
• Additional risk minimisation measures The Marketing Authorisation Holder (MAH) shall ensure that, prior to launch, all physicians who are expected to prescribe/use Cimzia are provided with a physician information pack containing the following:
Imetnik dovoljenja za promet mora pred dajanjem zdravila na trg zagotoviti, da prejmejo vsi zdravniki, za katere se pričakuje, da bodo predpisovali/uporabljali zdravilo Cimzia, paket z informacijami za zdravnike, ki vsebuje:
Overall, 16% of patients had prior TNF-antagonist exposure.
Celokupno je 16 % bolnikov že predhodno uporabljalo zaviralce TNF.
The use of adequate contraception should be considered for women of childbearing potential.
Pri ženskah v rodni dobi je treba razmisliti o uporabi ustrezne kontracepcije.
Cimzia was administered subcutaneously in combination with oral MTX for a minimum of 6 months with stable doses of at least 10 mg weekly for 2 months in both trials.
Zdravilo Cimzia so dobivali subkutano v kombinaciji s peroralnim MTX najmanj 6 mesecev ob stabilnih odmerkih najmanj 10 mg tedensko 2 meseca v obeh študijah.
Do not stop using Cimzia without talking to your doctor first.
Če ste prenehali uporabljati zdravilo Cimzia Zdravila Cimzia ne smete prenehati uporabljati, ne da bi se prej posvetovali z zdravnikom.
Manufacturer UCB Pharma S.A. Chemin du Foriest B-1420 Braine l'Alleud Belgium
Izdelovalec UCB Pharma S.A. Chemin du Foriest B-1420 Braine l'Alleud Belgija
*These events have been related to the class of TNF-antagonists, but incidence with certolizumab pegol is not known.
*Te dogodke povezujejo s skupino zaviralcev TNF, vendar pa pogostnost pri zdravljenju s certolizumab pegolom ni znana.
Take care not to touch the needle or let the needle touch any surface.
Pazite, da se igle ne dotaknete s prsti, oziroma da se z njo česa ne dotaknete.
After proper training, the injection can be self-administered or given by another person, for example a family member or friend.
Če so bili za to ustrezno usposobljeni, si lahko bolniki zdravilo injicirajo sami ali pa to stori nekdo drug, na primer družinski član ali prijatelj.
If new skin lesions appear during or after therapy with Cimzia or existing skin lesions change appearance, tell your doctor.
Če se med zdravljenjem z zdravilom Cimzia ali po njem pojavijo nove kožne tvorbe ali pa se že obstoječe tvorbe spremenijo, o tem obvestite svojega zdravnika.
Patients had a mean time since diagnosis at baseline of 2.9 months and were DMARD naïve (including MTX).
Bolniki so imeli povprečni čas od postavitve diagnoze 2,9 meseca in se še niso zdravili z antirevmatiki DMARD (vključno z MTX).
Certolizumab pegol does not cross-react with rodent TNF.
Certolizumab pegol ne reagira navzkrižno z glodalčjim TNF.
The de-conjugated PEG component is rapidly eliminated from plasma and is to an unknown extent excreted renally.
Dekonjugirana komponenta PEG se hitro izloči iz plazme, nato pa v neznani količini iz telesa preko ledvic.
No mutagenic or clastogenic effects were demonstrated in preclinical studies.
Predklinične študije niso pokazale mutagenih ali klastrogenih učinkov.
This effect has been observed with the PTT-Lupus Anticoagulant (LA) test and Standard Target Activated Partial Thromboplastin time (STA-PTT) Automate tests from Diagnostica Stago, and the HemosIL APTT-SP liquid and HemosIL lyophilised silica tests from Instrumentation Laboratories.
Tak učinek so opazili pri naslednjih testih: PTT-LA (Lupus Anticoagulant) in STA-PTT (Standard Target Activated Partial Thromboplastin time) Automate proizvajalca Diagnostica Stago, ter HemosIL APTT-SP tekočina in HemosIL liofilizirani silicijev dioksid proizvajalca Instrumentation Laboratories.
Of the 783 patients initially randomised to active treatment in RA-I, 508 completed 52 weeks of placebocontrolled treatment and entered the open-label extension study.
Od 783 bolnikov, ki so bili na začetku randomizirano izbrani za aktivno zdravljenje v študiji RA-I, jih je 508 zaključilo 52tedensko s placebom nadzorovano zdravljenje in vstopilo v odprt podaljšek študije.
PEGylation, the covalent attachment of PEG polymers to peptides, delays the elimination of these entities from the circulation by a variety of mechanisms, including decreased renal clearance, decreased proteolysis, and decreased immunogenicity.
Pegilacija, kovalentna vezava polimerov polietilenglikola (PEG) na peptide, zakasni izločanje teh spojin iz krvnega obtoka prek različnih mehanizmov, vključno z zmanjšanjem ledvičnega očistka, proteolize in imunogenosti.
Cimzia has a high affinity for human TNFα and binds with a dissociation constant (KD) of 90 pM. TNFα is a key pro-inflammatory cytokine with a central role in inflammatory processes.
Zdravilo Cimzia ima visoko afiniteto za humani TNF-α in se veže z disociacijsko konstanto 90 pM. TNF-α je bistven provnetni citokin, ki ima osrednjo vlogo v procesu vnetja.
These results were maintained over 52 weeks of treatment in DMARD-naïve subjects.
Ti rezultati so bili pridobljeni v 52 tednih zdravljenja bolnikov, ki se predhodno niso zdravili z DMARD.
If you develop new or worsening symptoms of heart failure (e.g. shortness of breath or swelling of your feet), you must contact your doctor immediately.
Če se pri vas pojavijo novi ali se poslabšajo obstoječi simptomi srčnega popuščanja (npr. kratka sapa ali otekanje stopal), se takoj posvetujte s svojim zdravnikom.
Consequently, Cimzia can be used during breastfeeding.
Posledično se zdravilo Cimzia lahko uporablja med dojenjem.